NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc. (AXIM ® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has published a product pipeline chart on its website that highlights the timelines from pre-clinical to a new drug application (NDA) for its numerous intellectual property-protected cannabinoid-based products. The Company's product pipeline chart shows what stage of clinical trials each drug of AXIM® Biotech is in, the indication the drug is intended to treat and the expected date to receive an NDA from the U.S. Food and Drug Administration (FDA) and/or European Medicines Agency (EMA). The chart also shows the anticipated market introduction date of the Company's various functional food and nutraceutical products. "We wanted to provide our potential patients and investors with a clear snapshot of the numerous cannabinoid-based therapeutic products that we currently have undergoing clinical trials and when these products are anticipated to be on the market and approved by the FDA and EMA," said AXIM® Biotechnologies, Inc.'s Chief Executive Officer George E. Anastassov, MD, DDS, MBA. "Our company is continuing to develop cannabinoid-based drugs to find answers for health conditions with currently no known sustainable answers." View the product pipeline chart here. An AXIM ® Biotech breakthrough invention on pace to be fully registered by the EMA and FDA by the end of 2018 is the world's first patented cannabinoid controlled-release chewing gum: MedChew Rx™. Recently featured by Reuters global news agency, MedChew Rx™ will change the way that medicine is delivered to patients worldwide. Directly compared to a sublingually delivered cannabis-based product currently on the market for multiple sclerosis (MS) in the Reuters article, the potential economic impact for MedChew Rx™ is estimated at $4.8 billion USD - for spasticity and pain associated with MS.